About this item:

536 Views | 157 Downloads

Author Notes:

Corresponding author: Dennis R. Burton, Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA. burton@scripps.edu

Author contributions: B.M., D.G.C., G.S., D.H.B., and D.R.B. designed research; B.M., K.L., D.G.C., J.B.W., N.S., M.G.L., E.B., K.S., J.J.M., and S.L.S., performed research; B.M., A.P.H., A. G., P.W.H.I.P, and D.R.B. analyzed data; and B.M. and D.R.B. wrote the manuscript.

The authors wish to thank the Emory Center for AIDS Research (CFAR) Virology core for their technical support and the CHAVI-ID DMSRC (Data management scientific research component) and Arne Haahr Andreasen for help with the statistical analysis.

There are no conflicts of interest.


Research Funding:

This work was supported by the NIH/CHAVI-ID grant UM1 AI100663, NIH/NCRR grant P51RR000165, the Bill and Melinda Gates Foundation/International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium grants SFP 2120 and SFP 2121.

The Yerkes National Primate Research Center was supported by the Office of Research Infrastructure Programs/OD P51OD011132.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • Virology
  • HIV
  • mucosal transmission
  • neutralizing antibodies
  • vaccine

Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques

Show all authors Show less authors


Journal Title:



Volume 30, Number 10


, Pages 1543-1551

Type of Work:

Article | Post-print: After Peer Review


Objective: Passive administration of broadly neutralizing antibodies has been shown to protect against both vaginal and rectal challenge in the simian/human immunodeficiency virus (SHIV)/macaque model of HIV transmission. However, the relative efficacy of antibody against the two modes of exposure is unknown and, given differences in the composition and immunology of the two tissue compartments, this is an important gap in knowledge. To investigate the significance of the challenge route for antibody-mediated protection, we performed a comparative protection study in macaques using the highly potent human monoclonal antibody, PGT126. Design: Animals were administered PGT126 at three different doses before challenged either vaginally or rectally with a single dose of SHIV SF163P3. Methods: Viral loads, PGT126 serum concentrations, and serum neutralizing titers were monitored. Results: In vaginally challenged animals, sterilizing immunity was achieved in all animals administered 10 mg/kg, in two of five animals administered 2 mg/kg and in one of five animals administered 0.4 mg/kg PGT126. Comparable protection was observed for the corresponding groups challenged rectally as sterilizing immunity was achieved in three of four animals administered 10 mg/kg, in two of four animals administered 2 mg/kg and in none of four animals administered 0.4 mg/kg PGT126. Serological analysis showed similar serum concentrations of PGT126 and serum neutralization titers in animals administered the same antibody dose. Conclusion: Our data suggest that broadly neutralizing antibody-mediated protection is not strongly dependent on the mucosal route of challenge, which indicates that a vaccine aimed to induce a neutralizing antibody response would have broadly similar efficacy against both primary transmission routes for HIV.

Copyright information:

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

Export to EndNote